Illumina, Inc. $ILMN Stake Boosted by Handelsbanken Fonder AB

Handelsbanken Fonder AB lifted its holdings in Illumina, Inc. (NASDAQ:ILMN) by 27.7% during the third quarter, HoldingsChannel reports. The institutional investor owned 51,600 shares of the life sciences company’s stock after purchasing an additional 11,200 shares during the period. Handelsbanken Fonder AB’s holdings in Illumina were worth $4,900,000 as of its most recent filing with the SEC.

Other institutional investors have also modified their holdings of the company. Loomis Sayles & Co. L P boosted its stake in Illumina by 1.9% in the second quarter. Loomis Sayles & Co. L P now owns 4,225,529 shares of the life sciences company’s stock valued at $403,158,000 after acquiring an additional 78,317 shares during the period. AQR Capital Management LLC lifted its holdings in shares of Illumina by 55.3% in the 2nd quarter. AQR Capital Management LLC now owns 3,295,880 shares of the life sciences company’s stock worth $313,290,000 after purchasing an additional 1,174,295 shares during the last quarter. Geode Capital Management LLC lifted its holdings in shares of Illumina by 0.7% in the 2nd quarter. Geode Capital Management LLC now owns 2,869,187 shares of the life sciences company’s stock worth $272,921,000 after purchasing an additional 21,342 shares during the last quarter. Bank of America Corp DE boosted its position in Illumina by 1.9% during the 2nd quarter. Bank of America Corp DE now owns 1,930,843 shares of the life sciences company’s stock valued at $184,222,000 after purchasing an additional 35,167 shares during the period. Finally, Edmond DE Rothschild Holding S.A. grew its stake in Illumina by 140.1% during the 2nd quarter. Edmond DE Rothschild Holding S.A. now owns 1,428,692 shares of the life sciences company’s stock worth $136,312,000 after buying an additional 833,750 shares during the last quarter. Institutional investors own 89.42% of the company’s stock.

Illumina Stock Down 1.2%

Shares of NASDAQ:ILMN opened at $132.89 on Tuesday. The firm has a 50 day simple moving average of $135.03 and a 200 day simple moving average of $118.61. Illumina, Inc. has a 52 week low of $68.70 and a 52 week high of $155.53. The company has a debt-to-equity ratio of 0.55, a quick ratio of 1.72 and a current ratio of 2.08. The company has a market cap of $20.32 billion, a PE ratio of 24.38, a price-to-earnings-growth ratio of 2.57 and a beta of 1.45.

Illumina (NASDAQ:ILMN) last announced its quarterly earnings data on Thursday, February 5th. The life sciences company reported $1.35 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.26 by $0.09. The firm had revenue of $1.16 billion during the quarter, compared to the consensus estimate of $1.10 billion. Illumina had a return on equity of 31.04% and a net margin of 19.57%.The business’s revenue for the quarter was up 5.0% on a year-over-year basis. During the same period in the prior year, the business earned $0.95 EPS. Illumina has set its FY 2026 guidance at 5.050-5.200 EPS. As a group, research analysts expect that Illumina, Inc. will post 4.51 earnings per share for the current year.

Insider Activity at Illumina

In other news, insider Scott M. Davies sold 323 shares of the company’s stock in a transaction dated Friday, December 12th. The stock was sold at an average price of $136.09, for a total transaction of $43,957.07. Following the completion of the sale, the insider owned 17,887 shares in the company, valued at approximately $2,434,241.83. This represents a 1.77% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, SVP Patricia Leckman sold 2,370 shares of the company’s stock in a transaction that occurred on Wednesday, February 18th. The stock was sold at an average price of $116.18, for a total value of $275,346.60. Following the sale, the senior vice president directly owned 16,321 shares of the company’s stock, valued at $1,896,173.78. The trade was a 12.68% decrease in their position. The SEC filing for this sale provides additional information. Insiders own 0.17% of the company’s stock.

Wall Street Analysts Forecast Growth

ILMN has been the subject of several analyst reports. Stifel Nicolaus boosted their price target on shares of Illumina from $135.00 to $155.00 and gave the company a “buy” rating in a report on Tuesday, January 20th. UBS Group reiterated a “neutral” rating and issued a $135.00 price objective on shares of Illumina in a research report on Friday, February 6th. Canaccord Genuity Group upped their target price on shares of Illumina from $130.00 to $150.00 and gave the stock a “hold” rating in a research report on Monday, January 26th. Zacks Research lowered shares of Illumina from a “strong-buy” rating to a “hold” rating in a research note on Wednesday, December 31st. Finally, Piper Sandler reduced their price objective on Illumina from $195.00 to $170.00 and set an “overweight” rating for the company in a research report on Monday, February 9th. Six investment analysts have rated the stock with a Buy rating, ten have issued a Hold rating and two have assigned a Sell rating to the stock. According to MarketBeat, the stock has a consensus rating of “Hold” and an average price target of $129.69.

Illumina Company Profile

Illumina, Inc (NASDAQ: ILMN) is a global life sciences company that develops, manufactures and markets integrated systems for the analysis of genetic variation and function. Headquartered in San Diego, California and founded in 1998, Illumina offers a range of sequencing and array-based technologies used by academic researchers, clinical laboratories, pharmaceutical and biotechnology companies, consumer genomics firms and agricultural researchers to enable discovery, translational research and clinical applications.

The company’s product portfolio includes next-generation sequencing (NGS) platforms and associated consumables, microarrays for genotyping and methylation analysis, library preparation kits and targeted assays.